Navigation Links
Threshold Pharmaceuticals Announces Corporate Realignment

- Company to reduce workforce by approximately one-quarter, reduce expenses

and focus primarily on novel cancer program -

REDWOOD CITY, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced a corporate realignment to reduce expenses and focus its activities on its hypoxia-activated prodrug (HAP) program and the currently ongoing clinical trials of glufosfamide.

Corporate Realignment

The Company is committed to reducing cash burn and refocusing its research and development efforts. The Company is taking the following actions:

-- The Company will realign several areas of its operations and reduce

staff by approximately one-quarter from 44 employees to 32. As part of

this action, Cathleen Davis, the Company's vice president, Finance and

Controller and Kevin Kaster, the Company's senior vice president,

Corporate Development will leave the Company. Joel Fernandes, who is

currently the Company's assistant controller, will serve as senior

director, Finance and Controller, effective November 2, 2007. Cathleen

Davis and Kevin Kaster will continue to serve the Company as


-- The Company is planning to reduce consulting and other external


In connection with these actions, Threshold expects to pay severance benefits of approximately $1.2 million in the fourth quarter of 2007. The Company continues to expect cash used for operations to be in the range of $30 to $35 million in 2007. The Company currently expects cash and investments to be sufficient to fund projected activities at least through the first quarter of 2009. As of June 30, 2007, Threshold had $34.9 million in cash and investments.

"This is just one of several steps that Threshold is taking to bring greater focus to our HAP program that we believe holds great promise for the treatment of solid tumors," said Barry Selick, Threshold's chief executive officer. "Dr. John Curd's recent appointment as president and CMO, this realignment, and an aggressive partnering effort for glufosfamide will enable us to redirect our resources in a way to optimize the chances of successfully developing not only TH-302 but follow-on compounds from this program as well."

"Kevin Kaster is one of the most talented strategists and Intellectual Property attorneys I have had the pleasure of working with -- his counsel and dedication to Threshold has been invaluable since joining the Company in 2002 and I look forward to his ongoing contributions to the Company as a consultant," said Barry Selick, Threshold's chief executive officer. "Cathy Davis' superb financial and leadership skills were critical to Threshold over the last two years -- she has been a wonderful colleague and a highly valued member of our management team. I wish both Kevin and Cathy great success in their future endeavors."

Focused Development Efforts

The Company's research and development efforts will be primarily focused on:

-- TH-302, a hypoxia-activated prodrug designed to exploit low oxygen

levels in hypoxic tumor regions. TH-302 was discovered by Threshold

scientists and is currently in a Phase 1 clinical trial in solid

tumors. The preclinical data for this compound suggests impressive

activity against both primary tumors as well as their metastases.

-- Glufosfamide. This year, the Company plans to complete enrollment and

report results in the Phase 2 trial of glufosfamide in soft tissue

sarcoma and analyze preliminary efficacy data from the Phase 2 trial of

glufosfamide in ovarian cancer. The Company previously reported

positive Phase 2 data from a combination study with gemcitabine in

treating front line pancreatic cancer. More recently, the Company

announced that, upon interim analysis, it was stopping enrollment in a

small cell lung cancer trial based upon an insufficient number of


The Company will also continue to evaluate in-licensing opportunities to potentially add to its existing pipeline.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial progress and results, potential therapeutic uses and benefits of our product candidates and financial results, estimates and projections. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence, enroll or complete its anticipated clinical trials and analyze data, issues arising in the regulatory process and the results, the time and expense required to conduct such clinical trials, the results of such clinical trials (including product safety issues and efficacy results), the ability to achieve the intended benefits of the expense reductions and refocusing efforts, and the ability to in-license other compounds or programs. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website ( and on our website ( under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.


Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.


SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Calcium Supplements May Not Be Useful After A Certain Threshold Is Achieved
2. Gene determines pain threshold...
3. Drug Firm on the Threshold of Developing Dengue Vaccine
4. Supply of Radiopharmaceuticals Hampered by Attacks
5. FDA approves Watson Pharmaceuticals Oxytrol patch
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
8. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
9. Top Pharmaceuticals Influence Doctors Prescriptions
10. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
11. Personalized Medicine and Innovative Pharmaceuticals
Post Your Comments:
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the ... loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and ... hair, without the need for surgery, prescription pills, or topical foams. , “Capillus272™ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology: